Trials / Completed
CompletedNCT03183934
A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial
A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- Anterogen Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1/2 clinical trial(ALLO-ASC-EB-101) for 24 months.
Detailed description
This is an open-label follow up study to evaluate the efficacy and safety for the subjects with ALLO-ASC-DFU treatment in phase 1/2 clinical trial (ALLO-ASC-EB-101) for 24 months. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALLO-ASC-DFU | ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa. This study is a follow-up study without intervention. Other Names: Allogenic adipose-derived mesenchymal stem cells |
Timeline
- Start date
- 2017-12-08
- Primary completion
- 2018-04-20
- Completion
- 2023-04-30
- First posted
- 2017-06-12
- Last updated
- 2023-08-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03183934. Inclusion in this directory is not an endorsement.